Hologic (HOLX) – Investment Analysts’ Recent Ratings Updates

Hologic (NASDAQ: HOLX) has recently received a number of price target changes and ratings updates:

  • 2/9/2018 – Hologic had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $48.00 price target on the stock.
  • 2/9/2018 – Hologic had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
  • 2/9/2018 – Hologic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock. They wrote, “HOLX’s F1Q18 revenue was consistent with its 1/8/18 preannouncement while its EPS beat consensus. Management reiterated its FY18 revenue guidance and raised its EPS guidance due to tax reform. We note that HOLX expects to reinvest about half of its tax savings in marketing campaigns and R&D. HOLX’s organic revenue growth increased to 4.9% (adjusted for selling days) in F1Q18 from 4.4% in F4Q17. Breast Health growth improved from last quarter driven by the stronger international sales while Diagnostics growth (excluding the Blood divestiture) slowed. We expect HOLX’s revenue growth to accelerate as its Aesthetics business returns to Y/Y growth and it faces easier comps and we reiterate our Buy rating.””
  • 2/9/2018 – Hologic was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $42.00 price target on the stock, down previously from $45.00.
  • 2/1/2018 – Hologic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock. They wrote, “FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 2/1/18. The number of digital breast tomosynthesis (DBT) units increased by 117 during January which represents a 10.0% Y/Y decrease. DBT unit penetration increased to 30.2% from 29.8% last month and facility penetration increased to 46.5% from 45.4% last month. We note that HOLX’s 3D mammography sales are less than 13% of its sales.””
  • 1/25/2018 – Hologic was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/19/2018 – Hologic was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $49.00 price target on the stock.
  • 1/13/2018 – Hologic was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/9/2018 – Hologic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock, up previously from $48.00.
  • 1/4/2018 – Hologic was upgraded by analysts at Bank of America Corp from a “neutral” rating to a “buy” rating. They now have a $50.00 price target on the stock.
  • 1/3/2018 – Hologic is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $50.00 price target on the stock.
  • 12/20/2017 – Hologic was upgraded by analysts at Cowen Inc to a “buy” rating. They now have a $52.00 price target on the stock.

Hologic, Inc. (NASDAQ HOLX) opened at $37.75 on Monday. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $10,438.97, a price-to-earnings ratio of 9.96, a price-to-earnings-growth ratio of 1.71 and a beta of 0.77. Hologic, Inc. has a twelve month low of $35.33 and a twelve month high of $46.80.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The company had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. Hologic’s revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.52 EPS. equities research analysts anticipate that Hologic, Inc. will post 2.25 earnings per share for the current fiscal year.

In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.88% of the company’s stock.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply